Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 1422616.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A double-blind clinical trial of clomipramine versus phenelzine was carried out on 30 patients suffering from DSM-III obsessive-compulsive disorder. The study period was 12 weeks, and the maximum doses used (from the fifth week on) were 225 mg/day for clomipramine (14 patients) and 75 mg/day for phenelzine (12 patients); four patients dropped out. Obsessive symptoms improved significantly in both drug groups, but there was no significant difference between groups. Depressive symptoms improved before obsessive ones.
Medical subject headings
- Clomipramine
- Obsessive-Compulsive Disorder
- Phenelzine